Literature DB >> 28071062

Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.

Juan María Vázquez Morón1, Héctor Pallarés Manrique2, Francisco H Machancoses3, Manuel Ramos Lora4, Carlos Ruiz Frutos5.   

Abstract

BACKGROUND: Fecal biomarkers, especially fecal calprotectin, are useful for predicting endoscopic activity in Crohn's disease; however, the cut-off point remains unclear. The aim of this paper was to analyze whether faecal calprotectin and M2 pyruvate kinase are good tools for generating highly accurate scores for the prediction of the state of endoscopic activity and mucosal healing.
METHODS: The simple endoscopic score for Crohn's disease and the Crohn's disease activity index was calculated for 71 patients diagnosed with Crohn's. Fecal calprotectin and M2-PK were measured by the enzyme-linked immunosorbent assay test.
RESULTS: A fecal calprotectin cut-off concentration of ≥ 170 µg/g (sensitivity 77.6%, specificity 95.5% and likelihood ratio +17.06) predicts a high probability of endoscopic activity, and a fecal calprotectin cut-off of ≤ 71 µg/g (sensitivity 95.9%, specificity 52.3% and likelihood ratio -0.08) predicts a high probability of mucosal healing. Three clinical groups were identified according to the data obtained: endoscopic activity (calprotectin ≥ 170), mucosal healing (calprotectin ≤ 71) and uncertainty (71 > calprotectin < 170), with significant differences in endoscopic values (F = 26.407, p < 0.01). Clinical activity or remission modified the probabilities of presenting endoscopic activity (100% vs 89%) or mucosal healing (75% vs 87%) in the diagnostic scores generated. M2-PK was insufficiently accurate to determine scores.
CONCLUSIONS: The highly accurate scores for fecal calprotectin provide a useful tool for interpreting the probabilities of presenting endoscopic activity or mucosal healing, and are valuable in the specific clinical context.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28071062     DOI: 10.17235/reed.2017.4542/2016

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

Review 1.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

2.  Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review.

Authors:  Monica State; Lucian Negreanu; Theodor Voiosu; Andrei Voiosu; Paul Balanescu; Radu Bogdan Mateescu
Journal:  World J Gastroenterol       Date:  2021-04-28       Impact factor: 5.742

3.  Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity.

Authors:  Krystyna Słowińska-Solnica; Dorota Pawlica-Gosiewska; Katarzyna Gawlik; Danuta Owczarek; Dorota Cibor; Halina Pocztar; Tomasz Mach; Bogdan Solnica
Journal:  Arch Med Sci       Date:  2021-01-05       Impact factor: 3.318

4.  Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.

Authors:  Wan-Ting Cao; Rong Huang; Shan Liu; Yi-Hong Fan; Mao-Sheng Xu; Yi Xu; Hui Ni
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

Review 5.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

6.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

Authors:  Shu-Chen Wei; Chien-Chih Tung; Meng-Tzu Weng; Jau-Min Wong
Journal:  Intest Res       Date:  2018-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.